Prostate Cancer News

We recommend rotating to landscape mode for ease of reading on mobile phones

This feed contains general updates from Google.ie based on the search term ‘prostate cancer’.

We recommend rotating to landscape mode for ease of reading on mobile phones

This feed contains news updates from the Europa Uomo website. (Updated Daily)

  • Reaching out in Eastern and Central Europe
    Europa Uomo’s Prostate Cancer Patient Officer, based in Poland, is helping to build new prostate cancer patient organisations in Europe Europa Uomo is supporting the growth new organisations for men with prostate cancer in Eastern and Central Europe – with the help of a young researcher and campaigner based in Warsaw. For the past 10 years, Izabella Pawlowska has helped with translation and administration for the Polish prostate cancer patients organisation, and in 2018 she began working with Europa Uomo to help build patient representation in other countries.  Izabella Pawlowska pictured at the 2018 Europa Uomo General Assembly in Dublin She has been working with Board member Stig Lindahl, making contact with prostate cancer patients in countries where there is currently no patient organisation, and offering support to existing organisations that need strengthening. This is valuable work, says Stig: “By providing a number of good examples from existing organisations in other parts of Europe, we hope they can find a ‘menu’ that is suitable to the environment in their own country.” Over the last year, Izabella has been working with men from Armenia, Latvia, Slovenia, Romania and Iceland as they attempt to develop support organisations. “Every country has different ... read more
    Published on March 7, 2019
    6 days ago
  • European PSA screening programme ‘on its way’
    A European PSA-based screening programme for prostate cancer is on its way, according to the European Association of Urology (EAU). Following publication of a new policy paper on prostate cancer screening, published with Europa Uomo and other organisations, EAU has announced it will be making the case for screening at important European meetings. It will be promoting the issue at the EU’s Innovative Partnership on Action Against Cancer (IPAAC) WP5 meeting on 20th May, and at the Romanian EU Presidency Conference on cancer prevention and cancer monitoring and data use. The hope is to influence cancer control plans of EU member states. This follows a meeting of European influencers at the European Parliament about the need for population-based prostate cancer screening programmes at a European level. The event, held on European Prostate Cancer Awareness Day (EPAD 19) on 22nd January, was hosted by Members of the European Parliament against Cancer Group. It focused on how early diagnosis will improve outcomes in prostate cancer patients across Europe. Europa Uomo Chair Andre Deschamps made a plea for a new strategy across the EU, based on increasing awareness, promoting PSA-led screening and treatment in specialised cancer centres. “Early treatment for ... read more
    Published on March 1, 2019
    2 weeks ago
  • General Assembly Europa Uomo 2019 – SAVE THE DATE!!
    Birmingham, UK June 14-15, 2019 The 2019 General Assembly of Europa Uomo will be held on Friday 14th and Saturday 15th of June in the Lloyd Room of Hornton Grange situated next to the Edgbaston Park Hotel where we are lodged.  The official language of the General Assembly is English.  The purpose of the meeting includes the presentation of the Board’s report for the year, the approval of the accounts and budget and election of members to the Board of Europa Uomo. Preliminary schedule: Thursday, June 13th 2019:        Board arrives in Birmingham Friday, June 14th 2018:        Morning: Board meeting / GA members arrive in Birmingham    Lunch    Afternoon (14:00 – 18:30): General Assembly    Evening (19:30): Dinner in a traditional pub Saturday, June 15th 2018:        Morning: General Assembly    Lunch (end 14:00)    Departure The post General Assembly Europa Uomo 2019 – SAVE THE DATE!! appeared first on . ... read more
    Published on February 27, 2019
    2 weeks ago
  • Active surveillance is psychologically difficult, study finds
    Active surveillance – monitoring rather than treating prostate cancer after diagnosis – may put a significant psychological burden on men with prostate cancer, according to a study by one of Europa Uomo’s members, the Danish prostate cancer patients’ organisation PROPA. PROPA surveyed members who were currently under active surveillance (AS), asking them how worried they were under AS. Out of a response of 191, 4% said they were seriously worried, 33% said they were somewhat worried, and 41% said they were a little worried. Nearly a third said they had regrets about delaying treatment. The study also found that there was strain on spouses and relationships. Sixty one per cent of respondents said that their sex-life were being influenced. Niels Einer-Jensen of PROPA points out that this patient view contrasts with data presented by urologists and psychologists, which suggests that AS has little adverse impact on psychological wellbeing. “The impact is not negligible and stronger than expected,” he says. “The medical profession should take the potential psychological load more into account during counselling,” he says. “A bigger investigation of the load and the reason for the discrepancies between this investigation and previous studies should be initiated.” The post ... read more
    Published on February 20, 2019
    3 weeks ago
  • Monitoring works for younger men too
    Active surveillance – monitoring rather than treating prostate cancer that hasn’t spread – is a good approach for men under 60 as well as older men, according to new research in the Journal of Urology. The study is significant because previous studies have indicated that younger men and their families are anxious that active surveillance may not be advantageous over time. Photo on Foter.com The American study compared two groups of men with low volume, low risk prostate cancer. One group began active surveillance when they were younger than 60 years and the other began when they were 60 or older. After six years, the investigators found no significant difference in progression-free survival, treatment-free survival, metastasis-free survival or prostate cancer specific survival. The authors, from Massachusetts General Hospital in Boston, conclude: “Active surveillance is a safe and effective approach which spares any properly selected men younger than 60 years with low risk prostate cancer from intervention, provides adequate time for intervention if required, and shows durable disease specific survival.” Read about this and other stories on developments in prostate cancer in the Europa Uomo newsletter https://www.europa-uomo.org/newsletters/ The post Monitoring works for younger men too appeared first on . ... read more
    Published on February 8, 2019
    1 month ago
  • Urgent action on prostate screening needed
    Europa Uomo has joined with European urological associations, scientific experts, policy makers and other patient organisations to call for national screening programmes for prostate cancer across Europe. In a new policy paper, launched in the European Parliament with support from MEPs, the organisations say that the European Parliament and EU member states should ensure that the European Commission considers whether PSA-based screening should be implemented at European level. The paper was issued jointly by Europa Uomo, Cancer Control Joint Action, the European Cancer Patient Coalition and the European Association of Urology (EAU) at a special event to mark European Prostate Cancer Awareness Day (EPAD). “The European Union can no longer continue to overlook the most common cause of cancer in men in Europe,” says the policy paper. Europa Uomo representatives at the EPAD meeting at the European ParliamentAction is urgent in the light of new evidence from the European Randomised Study of Screening for Prostate Cancer that PSA screening reduces prostate cancer mortality by 21%. “As such, PSA screening results in mortality reduction are obviously better than in breast or colon cancer screening,” says the paper. Europa Uomo Chair André Deschamps, who spoke at the EPAD event, said ... read more
    Published on January 23, 2019
    2 months ago
  • We can help pharma understand patient needs
    Organisations such as Europa Uomo are playing an important role in representing the views and needs of men with prostate cancer to the pharmaceutical industry, says Chairman André Deschamps. Having recently attended patient advisory meetings of the drug companies Janssen and Ipsen, Deschamps believes that the events – attended by representatives of people with many types of cancer and other illnesses – are helping companies better understand patient perspectives. Europa Uomo Chairman André Deschamps (front row, second right) with other patient group representatives at a recent Ipsen patient advisory board meeting“The content of those meetings is seldom about drugs,” he says. “It’s about providing patient information that is genuinely useful and understanding the real needs of patients and how drugs and their side effects can impact them.” “I think many companies are now beginning to realise that the information they get from the medical world about real needs is not necessarily the same as that they get from the patients. For example, it can be important for patients how a drug is taken – whether orally or intravenously, or via one tablet or many – but it is less important for clinicians because their main concern is ... read more
    Published on January 17, 2019
    2 months ago
  • New Year call for change from Europa Uomo Chair
    Politicians and policy makers across Europe need to change strategy to improve diagnosis, treatment and quality of life for men with prostate cancer. That is the message from Europa Uomo Chairman André Deschamps, in an article expressing concern that prostate cancer mortality rates are no longer decreasing across Europe. André Deschamps Deschamps points out that in some countries there is a significant increase in the number of cancers being detected at a late stage. A recent Europa Uomo questionnaire, with responses from 24 European states, found that less than 50% of men are aware of prostate cancer and that PSA-led early detection is promoted by healthcare professionals in only half of the countries. “We as patients urge our politicians and policymakers to adopt a change in strategy,” writes Deschamps, in an article for Health Europa Quarterly. He calls for public awareness campaigns, active encouragement of PSA testing (within EAU guidelines) and treatment in multidisciplinary cancer centres. “Some countries are still discouraging PSA-led early detection and claim that they do not harm their citizens with this,” he writes. “The arguments are mostly: less costs for the healthcare system, avoiding over treatment and that this policy has no influence on mortality rates.” ... read more
    Published on January 8, 2019
    2 months ago
  • High profile for November in Latvia
    The Latvian prostate cancer patient organisation organised Movember Latvia activities to inform men about when they should go to a doctor and what to do if they found they had cancer. During the month, the Movember Latvia messages gained a high profile in the media and at sporting events. As the month started, Helmuts Bēķis, a board member of the prostate organisation in Latvia, was interviewed during one of the breaks in the hockey game between Dinamo Riga and Lokomotiv Jaroslavl. The following day, board members and doctors again spoke about prostate cancer at a press conference in the city centre. One of the sponsors for the press conference was the company Husqvarna, whose motto for men is “Check your tools”. On 21st November there was a discussion meeting involving the urologic association, patients and media on the subject of “What to do next when you find out that you have a cancer”. On same day there was a Movember Latvija bus ride through Riga city. The message was: “Health should always be most important, so supporting the Movember Latvia movement we invite loving men – fathers, brothers, sons – to remind you to check and take care of your ... read more
    Published on December 18, 2018
    3 months ago
  • Europa Uomo’s mission to Armenia
    A Europa Uomo representative has met with cancer advocates, health professionals and politicians in Armenia, with a view to encouraging the formation of an organisation for men with prostate cancer in the country. Europa Uomo Vice Chairman, Stig Lindahl from Sweden, travelled to Artsakh, a northern province of Armenia Northern Armenia, for a meeting on male and female cancers. Travelling with representatives from Europa Donna, the European breast cancer coalition, Stig Lindahl gave a talk on living with prostate cancer in different parts of Europe and met with attending members of the public and doctors. The next day Stig Lindahl met with the provincial Prime Minister. This was followed by a meeting with doctors, nurses and patient representatives about the possibility of establishing a prostate patient organisation in Armenia. Stig said: “I discussed next steps with Nvard Kocharyan from Europa Donna and her team, and they are hoping to progress matters in the coming months with a view to making an application to join Europa Uomo in 2019.” The post Europa Uomo’s mission to Armenia appeared first on . ... read more
    Published on November 26, 2018
    4 months ago
  • Blue November
    Europa Uomo’s Italian member organisation, Europa Uomo Italia Onlus, has promoted the country’s first prostate cancer information campaign, named Blue November. Educational initiatives promoting men’s health were held throughout Italy during November, raising awareness of the risk of prostate cancer and providing information on how to address it. The campaign focused on information about alternative therapies, the importance of a multidisciplinary approach and the benefits of innovative surgical techniques. To mark the month, museums all over Italy shone blue lights on significant nude statues of men from Italy’s artistic heritage. Events were held in partnership with the Italian Ministry of Cultural Heritage and Activities. For more information: www.novembreazzurro.it (also available in English) The post Blue November appeared first on . ... read more
    Published on November 22, 2018
    4 months ago
  • Extending survival in patients with oligometastatic prostate cancer
    Patients whose cancer returns at multiple sites after treatment – called oligometastatic cancer – are generally thought incurable, but a recent Phase 2 trial found that a highly precise form of radiation can significantly extend these patients’ lives if the spread shows small tumors, and it does this without diminishing life quality. The approach was tested in patients with up to five metastatic sites, and doubled the time a patient lived without disease progression. The trial findings were presented last month at the American Society for Therapeutic Radiation Oncology (ASTRO) 2018 Annual Meeting. The trial explored the proposition that if the patient had only a few spots of cancer returning that these spots could be killed by a form of radiation known as Stereotactic Body Radiation Therapy [SBRT]*. This kind of radiation therapy uses small thin beams of radiation that are projected into the tumour from different angles. Because of the precision factor the dosage given is high and fewer sessions are required than with more conventional radiation. Researchers found that SBRT significantly extended patients’ lives by more than one year. While those receiving this approach lived for a median of three years and five months, patients on palliative radiation therapy lived ... read more
    Published on November 9, 2018
    4 months ago
  • Does ADT lead to a more aggressive type of prostate cancer?
    Androgen deprivation therapy (ADT) is an important treatment for prostate cancer.  But a new study has found that it sometimes promotes the transformation of prostate cancer cells into a more aggressive type resistant to treatment. Article: http://prostatecancernewstoday.com/2018/09/17/prostate-cancer-become-more-agressive-androgen-deprivation-therapy-study-finds/ Source:The Journal of Clinical Investigationhttps://www.jci.org/articles/view/99397 The post Does ADT lead to a more aggressive type of prostate cancer? appeared first on . ... read more
    Published on September 25, 2018
    6 months ago
  • Annual Report of the board 2017/2018
    Chairman’s Note The adoption of this third Annual Report for Europa Uomo at the 2018 General Assembly near Dublin, will mark the conclusion of my two three-year terms on the Board.  The past six years serving the membership in various offices of Europa Uomo have been both an honour and privilege.  My thanks go to all of you, and your colleagues at home for their support. When I came onto the Board in 2012, my basic objectives were the same as with my work for Tackle in the UK, viz., to improve the way we work as an organisation and to continue to work so that men get the right treatment at the right time.  As I review these past six years I recall how we struggled, through much debate and confusion, to get our statutes into sufficient order to finally get ourselves legally registered as a Belgian not-for-profit.  I was Treasurer for a time and being then responsible for our funding arrangements, I was concerned at how the lack of a business plan might hamper us, financially and organisationally, in the future.  There were also issues associated with our handling of the transition from the founders who built ... read more
    Published on August 13, 2018
    7 months ago
  • The IPCOR project
    Mr. David Galvin, Consultant Urologist and lead of the Irish Prostate Cancer Outcomes Research (IPCOR) project, gave a plenary address at the 2018 General Assembly of the European Prostate Cancer Coalition, Europa Uomo, in Malahide, Dublin on June 9th. In front of an audience of patient advocates from all over Europe, as well as Ireland, he described the approach and methodology of the project, which is collecting data from a variety of sources to generate an outcome-based national tumour registry for prostate cancer in Ireland. It is expected that analysis of the data in the registry will be used to inform patient care and decision making long into the future. The IPCOR project is supported by the Irish Cancer Society and the Movember Foundation. It is part of a global effort called TruNTH Global Registry, funded by Movember, to improve outcomes and the quality of patient care in prostate cancer. It will generate a registry of useful, high-quality data as part of a clinical research study to evaluate the outcomes of different care paths in prostate cancer, and how satisfied patients are with those outcomes. The ultimate aim is to allow clinicians to stop pursuing expensive treatments that have poor ... read more
    Published on June 21, 2018
    9 months ago